Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Hoffmann-La Roche
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02951429CT.gov Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension | — | Completed | — | — | — |
NCT01382368CT.gov Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients | — | Unknown | — | — | — |
NCT00981747CT.gov Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | — | Terminated | — | — | — |
NCT00625079CT.gov Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Idiopathic Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sildenafil (this asset) | Hoffmann-La Roche | Approved | BB · 65 |
| Pirfenidone | Endeavor Biomedicines, Inc. | P4 | A |
| Acetylcysteine | Endeavor Biomedicines, Inc. | P4 | BBB |
| Nintedanib | Mannkind Corporation | P4 | BBB |
| Prednisone | Fondation Hôpital Saint-Joseph | P3 | BB |
| hsk44459 | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| Nerandomilast | Boehringer Ingelheim | P3 | BB |
| hec585 | Sunshine Lake Pharma Co., Ltd. | P3 | B |
| Nal Er | Trevi Therapeutics | P3 | B |
+41 more in the Idiopathic Pulmonary Fibrosis cohort
Other indications for Sildenafil
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pulmonary Hypertension | — | P4 | BB · 71 |
| Sickle Cell Disease | — | P4 | BB · 68 |
| Erectile Dysfunction | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sildenafil in Idiopathic Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sildenafil-idiopathic-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →